Recent News

• 08.06.2026 - Q2 2026 Lantheus Earnings Conference Call
• 08.06.2026 - Q2 2026 Lantheus Earnings Conference Call
• 08.06.2026 - Lantheus Reports Second Quarter 2026 Financial Results
• 08.03.2026 - Curium Announces Definitive Agreement to Merge with Lantheus
• 08.03.2026 - Curium Announces Definitive Agreement to Merge with Lantheus
• 07.23.2026 - Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
• 07.23.2026 - Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
• 06.26.2026 - Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
• 06.26.2026 - Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
• 06.09.2026 - Goldman Sachs 47th Annual Global Healthcare Conference

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 08.04.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.04.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.04.2026 - 8-K Current report
• 08.03.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.03.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.03.2026 - EX-99.1 EX-99.1
• 08.03.2026 - 8-K Current report